• Home
  • About Us
  • Calendar
  • Facebook
  • Twitter

Sleep Scholar

Sleep Scholar for Sleep Medicine Professionals

  • Calendar
  • About Us
You are here: Home / Archives for August 2011

Lack of Deep Sleep Tied to Hypertension

August 31, 2011 by Randy Clare 2 Comments
August 31, 2011, 9:00 AM NY Times Article

By ANAHAD O’CONNOR

Men who get the least deep sleep each night have a higher risk of hypertension, new research shows.

Rahav Segev for The New York Times

Earlier studies have tied chronic sleep disorders and low levels of sleep to greater risks of heart disease and obesity, and even reduced life span. But the new study,published in the journal Hypertension, is one of the first to find that it’s not just how much you sleep, but the the quality of your nightly slumber that can affect your risk for high blood pressure.

The goal of the study, carried out by researchers at Harvard Medical School and elsewhere, was to look specifically at the slow-wave stages of sleep, which make up about 90 minutes to two hours of a normal night’s rest and represent the deepest hours of sleep. To study the effect of deep sleep on health, the scientists followed 784 healthy men who were part of an ongoing sleep study and did not have signs of high blood pressure at the start of the research. During the three-and-a-half year study, the men had their blood pressure checked at various times, and their levels of slow-wave sleep were monitored at home by a machine.

After controlling for a number of variables, the researchers found that the men who spent the least time in slow-wave or deep sleep were the most likely to develop high blood pressure. Although a night of normal sleep should consist of about 25 percent slow-wave sleep, the men in the study who were at highest risk for hypertension managed to enjoy deep sleep for no more than 4 percent of their total sleep each night.

The researchers found that the men with the least deep sleep were more likely to have sleep apnea and tended to sleep less over all.

“But those conditions did not completely explain their lack of slow-wave sleep,” said Dr. Susan Redline, an author of the study and a professor of sleep medicine at Harvard Medical School and Brigham and Women’s hospital.

Dr. Redline said that although the study followed only men, she believes the results would also apply to women who fail to get enough deep sleep.

During slow-wave sleep, the brain’s electrical activity slows down, as do a person’s heart rate, adrenaline levels and blood pressure. The average person’s blood pressure falls about 10 millimeters of mercury during slumber, a dip that largely occurs when deep sleep sets in.

This nightly fall in blood pressure is a “good thing,” said Dr. Redline. When blood pressure doesn’t fall at night, the condition is called “nondipping,” and it’s a risk factor for heart disease.

“Not having that nightly dip might directly influence daytime blood pressure,” said Dr. Redline.

It’s also known that the areas of the brain that regulate sleep patterns have “a lot of crosstalk with areas of the brain that release hormones and other mediators that influence blood pressure,” Dr. Redline said. When those areas of the brain are not entering slow-wave sleep, she added, it may interfere with various brain signals that influence blood pressure.

Whether you get an adequate amount of slow-wave sleep can be influenced by a number of factors. Any condition that disrupts your sleep at night — for example, loud snoring, sleep apnea or restless legs syndrome — can shorten your slow-wave sleep, as can medications. Even your age can have an effect: Deep sleep declines as you get older.

There is also data showing that what you do during the day can make a difference. Studies show that being more physically and cognitively active can increase the amount of time you spend in deep sleep at night.

“Some of that research comes from animals,” Dr. Redline said. “If you give animals more tasks to do during the day they have more slow-wave sleep at night.”

The only way to know precisely the amount of time you drift into deep sleep each night is through an overnight sleep study. But the key, Dr. Redline said, is to assess whether you feel rested in the morning and alert and ready to go after seven to eight hours of sleep.

“If you’re feeling tired and unrefreshed after a full night’s sleep,” she said, “that’s a good indication you need to talk to your doctor, and then your doctor would decide whether you need to see a sleep specialist.”

Filed Under: Uncategorized

Cardiovascular regulation in different sleep stages in the obstructive sleep apnea syndrome.

August 29, 2011 by Randy Clare Leave a Comment
Gapelyuk A, Riedl M, Suhrbier A, Kraemer JF, Bretthauer G, Malberg H, Kurths J, Penzel T, Wessel N.

Source

Department of Physics, Humboldt-Universität zu Berlin, Berlin, Germany.

Abstract

Abstract Heart rate and blood pressure variability analysis as well as baroreflex sensitivity have been proven to be powerful tools for the assessment of autonomic control in clinical practice. Their ability to detect systematic changes caused by different states, diseases and treatments shall be shown for sleep disorders. Therefore, we consider 18 normotensive and 10 hypertensive patients suffering from obstructive sleep apnea syndrome (OSAS) before and after a three-month continuous positive airway pressure (CPAP) therapy. Additionally, an age and sex matched control group of 10 healthy subjects is examined. Linear and nonlinear parameters of heart rate and blood pressure fluctuation as well as the baroreflex sensitivity are used to answer the question whether there are differences in cardiovascular regulation between the different sleep stages and groups. Moreover, the therapeutic effect of CPAP therapy in OSAS patients shall be investigated. Kruskal-Wallis tests between the sleep stages for each group show significant differences in the very low spectral component of heart rate (VLF/P: 0.0033-0.04 Hz, p<0.01) which indicates differences in metabolic activity during the night. Furthermore, the decrease of Shannon entropy of word distribution as a parameter of systolic blood pressure during non-REM sleep reflects the local dominance of the vagal system (p<0.05). The increased sympathetic activation of the patients leads to clear differences of cardiovascular regulation in different sleep stages between controls and patients. We found a significant reduction of baroreflex sensitivity in slow wave sleep in the OSAS patients (Mann-Whitney test, p<0.05) compared to controls, which disappeared after three months of CPAP therapy. Hence, our results demonstrate the ability of cardiovascular analyzes to separate between healthy and pathological regulation as well as between different severities of OSAS in this retrospective study.

Biomed Tech (Berl). 2011 Aug;56(4):207-13.

 

Filed Under: Uncategorized

Descriptive analysis of central sleep apnea in childhood at a single center

August 24, 2011 by Randy Clare Leave a Comment
Kritzinger FE, Al-Saleh S, Narang I.

Source

Division of Pediatric Respiratory Medicine, Hospital for Sick Children, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada; Christiaan Barnard Memorial Hospital, Cape Town, South Africa. drkritzinger@thrivingkids.co.za.

Abstract

Data on central sleep apnea (CSA) and its significance in children are limited. Our objectives were to describe the polysomnogram (PSG) characteristics and clinical features of children with significant CSA at a single pediatric sleep center.

STUDY DESIGN AND METHODS:

A retrospective chart review of children diagnosed with CSA on a PSG, from January 2007 to December 2008, was performed. All the PSG’s were performed in the pediatric sleep laboratory at The Hospital for SickChildren in Toronto, Canada. All children diagnosed with significant CSA with a PSG was eligible for inclusion. Each PSG was conducted and scored according to the American Academy of Sleep Medicine standard. Significant CSA was defined as a central apnea index (CAI) of >5 events/hr. Outcome for each patient was defined by the percentage change in the CAI at follow up.

RESULTS:

52/969 (5.4%) patients had a CAI > 5/hr on a baseline PSG. Of the 25/52 (13 males) patients who met inclusion criteria, the median age was 19 months (range 3-156 months) and their median BMI z score was +0.27 (range -2.95 to 3.02). The median CAI was 11 events/hr (range 6-198/hr). The mean oxygen saturations ranged from 92.8% to 98.5%, with a median of 97%. Six (24%) patients had associated sleep-related hypoventilation and none of the patients had periodic breathing. The commonest identifiable risk factor for CSA in the study population was a neurological disorder.

CONCLUSIONS:

This study confirms that CSA is an important finding in a significant number of young children referred for an evaluation for suspected sleep related disordered breathing. Any child diagnosed with CSA warrants full clinical assessment, including neuro-imaging. Future research should aim to evaluate the long term outcome of significant CSA.

 

Pediatr Pulmonol. 2011 Apr 25. doi: 10.1002/ppul.21469.

Filed Under: Uncategorized

Scottsdale Study Club September and October Dates

August 23, 2011 by Randy Clare 1 Comment

The Scottsdale Study Club will host a continuium for dentists that are interested in adding sleep disorder treatment to their practice. The series will allow the Dr to evaluate and treat patients using a medical model.

The initial class will allow the Dr and their staff to properly evaluate patients for evaluation and management guidelines to fit the treatment codes to the diagnostic codes. Without the proper evaluation forms the practice will face denial of their claims.The staff will be provided with scripted forms to accurately record the patients symptoms for insurance processing.

The appointment evaluation forms will be provided for the Dr and staff for each separate appointment from initial evaluation until the patient has reached MMI, maximum medical improvement improvement.

The proper dental evaluation as well as the medical evaluation will be discussed including the proper radiographic and psychologic records needed for medical insurance.

Discussion of medicare guidelines as well as becoming in network providers for medical insurance providers will be covered. Compliance manuals for medicare will be discussed as well as the process for becoming a Credentialed Dental Facility from the AADSM.

The overnight PSG class also in Scottsdale will meet the requirements for the diplomate exam of the AADSM with in lab observation of the patient as well as the written exam questions.

The Oct 14, 15 class will begin the evaluation of patients for sleep bruxism, orofacial pain and TMD dysfunstion and Obstructive Sleep Apnea. The ability of the dentist to properly evaluate and treat these patients will be discussed in detail. Various treatments as well as oral devices will be shown and discussed so the attendee can begin patient evaluation and treatment.

The mentors and instructors  for the class have many years experience in treatment of these patients. The class is by invitation only and will be kept to a small group for detailed instruction for the attendees. The class fee is $1495 per session for the Dr and 2 staff. Each staff memeber after that will be $495.  Study Club registration office can be reached at 760-633-4162.

 

Location

SleepScholar Study Club General Session

14635 N Kierland Blvd., Ste. 154

Scottsdale, AZ, 85254

Seating is limited and will be assigned on a first come first serve basis

Calendar of Events 2011

September 16- 17, 2011

Where are the patients?

  • Evaluation of dental patients at each dental appointment for signs and symptoms of untreated sleep disorders
  • Conversion from dental to medical
  • Dental insurance vs. Medical Insurance including Medicare
    AASM as well as AADSM guidelines for treatment in the dental office
  • Hands-on workshop for patient evaluation and treatment

Mentor Spotlight

Dr. Rodney Willey, Peoria, IL

Dr. Michael Childres, Bradenton, FL

Dr. Michael Gluhareff, Ocala, FL

Dr. Edward Spiegel, Scottsdale, AZ

Dentists and one staff member will learn proper patient evaluation, examination, jaw registration, and dental and medical records.

 

Location for the Overnight Polysomnography Workshops

Embassy Suites

4415 E. Paradise Village Pkwy South
Phoenix, AZ 85032

 

Calendar of Events 2011

September 23-25, 2011

Overnight PSG (Limited to 12 Dentists)

  • Overnight Sleep Polysomnography two-night PSG of patient for diagnosis as well as second night treatment with CPAP and Oral Appliance.
  • Dentist will see actual examination of patient as well as patient prepared for PSG with evaluation and live data being recorded.
  • Discussion of PSG results as well as a comparison of CPAP and OA treatment as recorded by the PSG.

Mentor Spotlight
Mr. Jeffory Wyscarver

Mr. Randy Clare

Dr. Edward Spiegel

 

October 14-15, 2011

Bruxism, TMD and Sleep

  • Etiology of Bruxism, use of the Ordinal Scale as well as tie in to TMD and Sleep Disorders
  • Evaluation of the patient, documentation and medical billing for ABI
  • Treatment options in the pediatric patient as well as adult patient
  • Orthodontic evaluation and early treatment
  • TMD evaluation of patients as well as treatment planning
  • Sleep patient present with symptoms of pain and pre existing conditions
  • Hands-on evaluation of patient dentition and treatment planning
  • Proper medical referral and medical billing

Mentor Spotlight

Dr. Devin Croft, Orthodontist, Peoria, AZ

Dr. Bradley Eli, UCLA 2-year residency, San Diego, CA

Dr. Edward Spiegel, Scottsdale, AZ

Location for Apnea and TMJ/Headache Workshops

Vistancia Ortho

9772 W. Yearling Rd Suite A-1600

Peoria, AZ 85383

 

October 21-22, 2011

Chairside Sleep Apnea

  • Medical legal aspects involved in treating the Bruxing, TMD and Sleep patient
  • Health care attorney will review medical insurance guidelines. Medicare guidelines including anti-fraud, anti-kickback and Stark Laws.
  • Informational seminars for Snoring, TMD as well as Sleep Disorders.
  • How to organize market and follow-up.
  • Working with the sleep lab.  How to legally refer patients with medical insurance as well as Medicare.

Mentor Spotlight

Dr. Rodney Willey, Peoria, IL

Dr. Bradley Eli, San Diego, CA

Dr. Edward Spiegel, Scottsdale, AZ

 

 

Filed Under: Uncategorized

Maxillary, mandibular, and chin advancement: treatment planning based on airway anatomy in obstructive sleep apnea.

August 23, 2011 by Randy Clare 2 Comments
Schendel S, Powell N, Jacobson R.

Source

Stanford University, Palo Alto, CA, USA. sschendel@stanford.edu

Abstract

Surgical correction of obstructive sleep apnea (OSA) syndrome involves understanding a number of parameters, of which the 3-dimensional airway anatomy is important. Visualization of the upper airway based on cone beam computed tomography scans and automated computer analysis is an aid in understanding normal and abnormal airway conditions and their response to surgery. The goal of surgical treatment of OSA syndrome is to enlarge the velo-oropharyngeal airway by anterior/lateral displacement of the soft tissues and musculature by maxillary, mandibular, and possibly, genioglossus advancement. Knowledge of the specific airway obstruction and characteristics based on 3-dimensional studies permits a directed surgical treatment plan that can successfully address the area or areas of airway obstruction. The end occlusal result can be improved when orthodontic treatment is combined with the surgical plan. The individual with OSA, though, is more complicated than the usual orthognathic patient, and both the medical condition and treatment length need to be judiciously managed when OSA and associated conditions are present. The perioperative management of the patient with OSA is more complex and the margin for error is reduced, and this needs to be taken into consideration and the care altered as indicated.

J Oral Maxillofac Surg. 2011 Mar;69(3):663-76.

Filed Under: Uncategorized

North suburban man accused of bilking sleep-disorder investors

August 22, 2011 by Randy Clare Leave a Comment

as reported in the Chicago Tribune

July 27, 2011|By Cynthia Dizikes | Tribune reporter

 

A north suburban man has been charged with defrauding about $4 million from investors for a now-defunct sleep disorder business, spending much of the money on a Lake Forest mansion, a tattoo parlor and family vacations to Italy, Nevada, Florida and Alaska.

Kenneth Dachman, 52, allegedly wooed investors from about June 2008 to September 2010 to help fund Central Sleep Diagnostics and Advanced Sleep Devices, which purported to treat sleepapnea and sleep-related illnesses and sell related equipment.

The more than 50 investors who jumped onboard believed their money would be used to purchase sleep-related equipment, rent office space and retain and pay physicians to review diagnostic studies, according to the indictment.

In some cases, Dachman personally guaranteed he would repay investors’ principal, as well as monthly payments equal to between 5 and 24 percent annually, authorities said.

Instead, the indictment alleges that Dachman misappropriated at least $2 million of the co-mingled funds. Dachman was charged with 11 counts of wire fraud.

In addition to the house and multiple vacations, authorities said Dachman also purchased a new sport utility vehicle, rare books and antiques and funded gambling in Las Vegas and spent more than $200,000 on personal stock trading.

While pulling together money for his businesses, Dachman allegedly did not tell investors that he had almost no assets and that he had declared personal bankruptcy on seven prior occasions. He also falsely told investors that he had a PhD from Northwestern University, according to the indictment.

The indictment seeks at least $4 million as well as a 2008 Land Rover.

Each count of wire fraud carries a maximum penalty of 20 years in prison and a $250,000 fine.

Dachman was featured in a front-page Tribune story last October in which a lawyer who represented investors allegedly duped in the sleep disorder scam called him “a serial financial predator” who over the years created different businesses only to use investments for personal expenses and then declare bankruptcy to avoid his debts.

cdizikes@tribune.com

Filed Under: Uncategorized

WideMed wins CE Mark for mobile sleep apnea monitor

August 22, 2011 by Randy Clare Leave a Comment

WideMed plans to begin marketing the Morpheus Ox system in Europe and the Far East during the fourth quarter.

18 August 11 15:49, Globes’ correspondent
WideMed Ltd. (TASE:WDMD) has obtained EU CE Mark for its mobile sleep apnea system Morpheus Ox for home use. The system is based on a device made by Nonin Medical Inc. and WideMed’s mobile application and Morpheus platform for monitoring sleep apnea.The device’s interface receives photoplethysmography (PPH) signals, which are collated by an application developed by the company for mobile telephones.

The Morpheus Ox system can monitor, measure, and analyze snores and send accurate data to a physician about the patient’s respiration, apnea, oxygen levels, and heartbeat during the night.

WideMed said that it plans to begin marketing the Morpheus Ox system in Europe and the Far East during the fourth quarter, and that it undergoing regulatory procedures with the Food and Drug Administration (FDA) to approve the device for marketing in the US.

WideMed’s share price rose 12.1% by mid-afternoon to NIS 0.65, giving a market cap of NIS 10.5 million.

Published by Globes [online], Israel business news

Filed Under: Uncategorized

F&P Healthcare fleeing high dollar

August 22, 2011 by Randy Clare Leave a Comment

Fisher & Paykel Healthcare, whose strong sales growth in the US is being clipped by an equally strong kiwi dollar, will expand production in Mexico and target sales growth in other currencies. The company “is acutely conscious of the effect of the high NZ dollar on shareholder returns,” said managing director Michael Daniell. ”Exchange rate volatility continues to be extreme, with the New Zealand dollar well above its long-term average value, particularly when compared to the US dollar and euro.”

Foreign exchange hedging earned $38 million in Healthcare’s latest year, when it posted record operating revenue of $506 million. But net profit fell 27% in New Zealand dollars, its reporting currency, to about $53 million. The decrease reflected “unfavourable exchange rate movements” which turned a 9% gain in sales in US dollars into a 1% gain in the kiwi currency to $506 million. So far this year, the kiwi dollar has advanced 6% against the greenback and traded recently at 82.17 US cents. But on a trade-weighted basis the gain is only 2%. The US Dollar Index, which measures the greenback against a basket of major currencies, has declined 6.1%.

Healthcare gets 54% of operating revenue in US dollars and 23% in euros. The kiwi has slipped just 1.5% against the euro this year. Assuming the kiwi dollar trades between 80 cents and 85 cents for the rest of the financial year, the company sees annual revenue of between $515 million and $530 million, Daniell told the meeting. That would be up from $503 million last year. Annual net profit is forecast at $60 million to $65 million, down from the range it gave in May of $62 million to $76 million and down from last year’s $71.6 million.

The company’s response has been to expand its plant in Mexico, where its operations have widened from manufacturing its respirators and sleep apnea masks to direct sales and even R&D. Sleep apnea may be an untapped global market, based on figures the company cites of 10 million people who have the condition worldwide where they stop breathing momentarily during sleep. This has been linked to heart disease and other ailments, it says.  It plans to generate most of the growth in its consumables products by ramping up output at its factory in Tijuana, where it began manufacturing in April last year.

“We are achieving the expected manufacturing cost savings, and the Mexico facility is beginning to contribute positively to operating margin,” Daniell said. The shift to Mexico has accelerated. Originally half of its high-volume consumables were to be made there within fives years. By speeding up the move, it will “achieve the expected $20 million of annual savings sooner.”

The shares rose 1.7% to $2.38 on the NZX on Friday.

Filed Under: Uncategorized

Comparison of portable apnea monitors in the detection of apnea episode during daytime rest

August 19, 2011 by Randy Clare Leave a Comment
Yamada C, Kosuda M, Tomihara T, Shimazu C, Ochiai M, Furukawa T, Miyazawa Y.

Source

Department of Central Laboratory, Teikyo University Hospital, Itabashi-ku, Tokyo 173-8606, Japan.

Abstract

Although polysomnography (PSG) is the golden standard for the diagnosis of sleep apnea syndrome (SAS), access to this procedure is limited because it requires special institution and trained technicians. Therefore, many portable recording devices have been developed for detection of SAS including home monitoring. The present study evaluated the usefulness of four portable devices in detecting apneic events. The four devices are, (1) FM-500 thermister sensor type III device, (2) LS-300 pressure sensor type III device, (3) Morpheus pressure sensor type III device, and (4) SD-101, a sheet-type type IV device that detects chest wall movement. This study included 1,114 patients who underwent a daytime rest session during a routine clinic visit. The subjects were asked to remain quiet and in a supine position in a dark room. We compared the respiratory disturbance index (RDI) and number of oxygen desaturation events (OD) measured by the four portable devices in each patient. The RDI and number of OD measured by the device using the thermister sensor were significantly lower than those measured by the three other devices. These findings suggest that when using a portable recording device to screen for SAS, the characteristics of the device should be taken into account.

Rinsho Byori. 2011 Jun;59(6):543-8.

 

Filed Under: Uncategorized

Apria, Rotech report earnings, discuss performance Apria:

August 15, 2011 by Randy Clare Leave a Comment

We like our chances under competitive bidding, but there are no guarantees

 

LAKE FOREST, Calif. – Apria Healthcare last week reported net revenues of $576.3 million for the three months ended June 30, 2011, compared to $518.2 million for the same period last year. It reported a net loss of $9.4 million this year vs. a net income of $3.4 million last year.

Apria reported net revenues of $1.1 billion for the six months ended June 30, 2011, compared to $1 billion for the same period last year. It reported a net loss of $30.5 million this year vs. a net income of $2.6 million last year.

Apria’s growth was due to an increase in its home infusion therapy segment revenue and its acquisition of Praxair’s assets. That was partially offset by the non-renewal, termination of or changes to certain payer contracts, among other factors.

In an accompanying 10-Q filed with the Securities and Exchange Commission (SEC), Apria shared the following details on its performance:

“To date, we have made significant progress across a number of identified initiatives targeting expected annual savings of approximately $179 million, of which we realized approximately $166 million through June 30, 2011.”

In the three months ended June 30, 2011, about 24% and 6% of Apria’s net revenues were reimbursed by Medicare and Medicaid, respectively. In the six months ended June 30, 2011, about 23% and 7% of its revenues were reimbursed by the two programs. Managed care represents the remaining 70% of revenues.

On July 11, Apria announced that James Gallas, its executive vice president and chief administrative officer, would cease to oversee revenue management, information technology and certain related functions. Management of those functions will be assumed by other members of senior management. Gallas will assume a special projects role until Feb. 28, 2012.

Apria expects Round 1 of competitive bidding to impact net revenues in the fiscal year ending Dec. 31, 2011, by about $8 million. Assuming Round 2 includes the same product categories, bidding rules and markets planned by CMS, it estimates $110 million of net revenues for the fiscal year would be subject to competitive bidding.

On its chances of succeeding under competitive bidding, Apria stated: “We believe that our geographic overage, clinical marketing programs and purchasing strength provide competitive advantages to maintain and enhance market share under Medicare competitive bidding. However, there is no guarantee that we will be selected as a winning contract supplier in any future phases of the program and be awarded competitive bidding contracts by CMS or that we will garner additional market share.”

Rotech treads water

‘We believe volume increases will more than offset reductions in reimbursement’

ORLANDO, Fla. – Rotech Healthcare last week reported net revenues of $122.4 million for the three months ended June 30, 2011, compared to $124.3 million for the same period last year. It reported a net loss of $2 million this year vs. a net income of $3.4 million last year.

Rotech reported net revenues of $243.9 million for the six months ended June 30, 2011, compared to $247.7 million for the same period last year. It reported a net loss of $4.9 million this year vs. $3.3 million last year.

“In comparing second quarter of 2011 with that of 2010, we are pleased to report continued improvement,” stated President and CEO Philip Carter in a release. “This was in spite of a $5.7 million decline in Medicare reimbursements.”

In its 10-Q, Rotech stated:

“During 2010, we substantially completed development of a new order intake system that will streamline our order intake processes and eliminate many of our current, paper-based processes. We have to date completed implementation of this system in approximately 10% of our operating locations and we expect full implementation by the end of 2011.”

On June 28, 2011, Rotech submitted its application for relisting its common stock on the NASDAQ Global Market.

Rotech relied on Medicare, Medicaid and other federally funded programs for 56.9% and 57% of its revenues for the three months and six months ended June 30, 2011, respectively. That’s compared to 58.4% and 58.1% for the same periods last year.

“The application of the new competitive bid rates in the Round 1 Rebid CBAs reduced our net revenue by approximately $0.9 million and $2 million for the three and six months ended June 30, 2011, respectively. We have experienced volume increases in the CBAs where we were awarded contracts, which we attribute to an increase in market share, during the three and six months ended June 30, 2011, and we believe that these volume increases will more than offset the reductions in reimbursement over time.”

As reported on HME newswire

Filed Under: Uncategorized
« Older Posts

Search

Editorial Board

Randy Clare
Managing Editor of SleepScholar and RespiratoryScholar
Dr. Steve Carstensen
Pankey Institute for Advanced Dental Education, American Academy of Dental Sleep Medicine.
Ruchir Patel MD
Founder & Medical Director at the Insomnia and Sleep Institute of Arizona.
Dr. John S. Viviano
AADSM Diplomate and member of various sleep organizations. Has lectured internationally on the treatment of Sleep-Disordered Breathing and the use of Acoustic Reflection.
Jeffroy Wyscarver
President, DDME Online, Sleep Lab Technology and Services for the Dental Community.
Claude Albertario
RPSGT, speaker, author and mentor in the field of sleep diagnostics with 25 yrs of management experience in one of New York's premier sleep centers.
Joseph Anderson
Co-Founder and Director of Education for Priority Health Education and Priority Scoring.
Todd Austin
Managed sleep labs and has 15 experience in sleep diagnostics and therapeutic systems. .
Marietta Bibbs
Sleep specialist and manager of Sleep and Neurodiagnostics at Morton Plant Mease Healthcare.
Bradley Eli DMD, MS
Director, San Diego Headache and Facial Pain Center / Sleep Treatment and Research Institute
Edward Grandi
Executive Director of the American Sleep Apnea Association.
Edward Michaelson MD
Board Certified in Pulmonary Medicine, Internal Medicine and Sleep Medicine
Ashley Truitt
Founder & Director of Dental Sleep Medicine Worldwide, Co-Founder of TPT Dental.

Upcoming Events

Georgia Association of Sleep Professionals
April 30, Atlanta, GA

Archives

  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • September 2010
  • August 2010

Random Posts

Benchmarking Improves the Sleep Business

Obstructive hypopnea and gastroesophageal reflux as factors associated with residual obstructive sleep apnea syndrome

Do patients at risk of sleep apnea have an increased risk of cardio-respiratory complications during endoscopy procedures?

A New Decade Means New Challenges in Education for Sleep Professionals

How to Scientifically Measure the Cost of Missing a Nights Sleep

Return to top of page

Copyright © 2013 Sleep Scholar